Physician profile
Mona Elsayed Aly Orady
NPI 1003970773
$223,593.54
in general payments reported to CMS, 2019-2025
22 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $25K · 2021: $33K · 2022: $24K · 2023: $9,088 · 2024: $1,372 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Education: $2,400 · Food and Beverage: $1,061 · Travel and Lodging: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,295.00 |
| Education | $2,400.00 |
| Food and Beverage | $1,061.47 |
| Travel and Lodging | $532.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170,186.35 | 2019-2025 | |
| Medicaroid, INC. | $19,349.03 | 2021-2024 | |
| Baxter Healthcare | $15,883.67 | 2022-2025 | Adept, Perclot, Hillrom - Cardiac Ambulatory Monitor |
| Lumenis, INC | $10,078.39 | 2019-2021 | |
| Teleflex LLC | $5,897.53 | 2019 | |
| Intuitive Surgical, INC. | $895.97 | 2019-2020 | |
| Acessa Health INC. | $277.71 | 2022 | |
| Amag Pharmaceuticals, INC. | $211.95 | 2019 | |
| Hologic Sales and Service, LLC | $204.11 | 2022-2024 | Acessa Provu System |
| Meditrina | $99.94 | 2024 | |
| Karl Storz Endoscopy-America | $97.29 | 2019 | |
| Ethicon US, LLC | $87.29 | 2019 | |
| Boston Scientific Corporation | $60.04 | 2022 | |
| Minerva Surgical, INC | $44.61 | 2023-2025 | |
| Myriad Women'S Health, INC. | $42.34 | 2023 | Myrisk |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $34.85 | 2025 | |
| Sumitomo Pharma America, INC. | $30.74 | 2025 | Myfembree |
| Myovant Sciences INC. | $29.22 | 2022 | |
| Medtronic, INC. | $28.30 | 2024 | V-Loc 180 |
| Shield Therapeutics INC | $19.45 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $18.76 | 2021 | |
| Mimedx Group, INC. | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Orady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.